Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes

The CONCEPTT trial compared real-time Continuous Glucose Monitoring (RT-CGM) to capillary glucose monitoring in pregnant women with type 1 diabetes. We analyzed CGM and glycated hemoglobin (HbA(1c)) measures in first (n = 221), second (n = 197), and third (n = 172) trimesters, aiming to examine targ...

ver descrição completa

Detalhes bibliográficos
Autores: Tundidor, D, Meek, CL, Yamamoto, J, Martinez-Bru, C, Gich, I, Feig, DS, Murphy, HR, Corcoy, R
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p4672
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4672
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573793
Access Level:acceso abierto
Palavra-chave:Continuous glucose monitoring
Type 1 diabetes
Pregnancy
HbA(1c) target
Time in range
id ES_fd353fc5e39daede212205f7ab8c3de2
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p4672
network_acronym_str ES
network_name_str España
repository_id_str
spelling Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 DiabetesTundidor, DMeek, CLYamamoto, JMartinez-Bru, CGich, IFeig, DSMurphy, HRCorcoy, RContinuous glucose monitoringType 1 diabetesPregnancyHbA(1c) targetTime in rangeThe CONCEPTT trial compared real-time Continuous Glucose Monitoring (RT-CGM) to capillary glucose monitoring in pregnant women with type 1 diabetes. We analyzed CGM and glycated hemoglobin (HbA(1c)) measures in first (n = 221), second (n = 197), and third (n = 172) trimesters, aiming to examine target glucose attainment and associations with pregnancy outcomes. CGM targets were Time-in-range (TIR) > 70%, Time-above-range (TAR) <25%, and Time-below-range (TBR) < 4%, and HbA(1c) targets < 6.5% (National Institute for Health and Care Excellence [NICE]) and HbA(1c) < 6.0% in second and third trimesters (American Diabetes Association [ADA]). TIR/TAR/TBR targets were achieved by 7.7/14.5/30.3% participants in first, 10.2/14.2/52.8% in second, and 35.5/37.2/52.9% in third trimesters. CGM target attainment was low but increased during pregnancy and with RT-CGM use. In the adjusted analyses, achieving TBR target was associated with a higher risk of pre-eclampsia and neonatal hypoglycemia. ADA HbA(1c) target attainment was low and unchanged during pregnancy (23.5/27.9/23.8%) but increased with RT-CGM use. In the adjusted analyses, HbA(1c) target attainment was associated with a lower risk of preterm birth, large-for-gestational age and neonatal hypoglycemia. We conclude that CONCEPTT trial participants had a low rate of CGM and of HbA(1c) target attainment. Attainment of CGM and NICE HbA(1c) targets increased throughout gestation and all targets (both NICE/ADA HbA(1c) and CGM) were more likely to be achieved by RT-CGM users, at 34 weeks' gestation. ADA HbA(1c) target achievement was independently associated with better perinatal outcomes, while the independent association of TBR target achievement with increased risk warrants further study. ClinicalTrials.gov Registration Identifier NCT01788527.MARY ANN LIEBERT, INC2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4672https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573793Diabetes Technology & TherapeuticsISSN: 15209156ISSNe: 15578593reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p46722026-06-14T12:41:47Z
dc.title.none.fl_str_mv Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
title Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
spellingShingle Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
Tundidor, D
Continuous glucose monitoring
Type 1 diabetes
Pregnancy
HbA(1c) target
Time in range
title_short Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
title_full Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
title_fullStr Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
title_full_unstemmed Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
title_sort Continuous Glucose Monitoring Time-in-Range and HbA(1c) Targets in Pregnant Women with Type 1 Diabetes
dc.creator.none.fl_str_mv Tundidor, D
Meek, CL
Yamamoto, J
Martinez-Bru, C
Gich, I
Feig, DS
Murphy, HR
Corcoy, R
author Tundidor, D
author_facet Tundidor, D
Meek, CL
Yamamoto, J
Martinez-Bru, C
Gich, I
Feig, DS
Murphy, HR
Corcoy, R
author_role author
author2 Meek, CL
Yamamoto, J
Martinez-Bru, C
Gich, I
Feig, DS
Murphy, HR
Corcoy, R
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Continuous glucose monitoring
Type 1 diabetes
Pregnancy
HbA(1c) target
Time in range
topic Continuous glucose monitoring
Type 1 diabetes
Pregnancy
HbA(1c) target
Time in range
description The CONCEPTT trial compared real-time Continuous Glucose Monitoring (RT-CGM) to capillary glucose monitoring in pregnant women with type 1 diabetes. We analyzed CGM and glycated hemoglobin (HbA(1c)) measures in first (n = 221), second (n = 197), and third (n = 172) trimesters, aiming to examine target glucose attainment and associations with pregnancy outcomes. CGM targets were Time-in-range (TIR) > 70%, Time-above-range (TAR) <25%, and Time-below-range (TBR) < 4%, and HbA(1c) targets < 6.5% (National Institute for Health and Care Excellence [NICE]) and HbA(1c) < 6.0% in second and third trimesters (American Diabetes Association [ADA]). TIR/TAR/TBR targets were achieved by 7.7/14.5/30.3% participants in first, 10.2/14.2/52.8% in second, and 35.5/37.2/52.9% in third trimesters. CGM target attainment was low but increased during pregnancy and with RT-CGM use. In the adjusted analyses, achieving TBR target was associated with a higher risk of pre-eclampsia and neonatal hypoglycemia. ADA HbA(1c) target attainment was low and unchanged during pregnancy (23.5/27.9/23.8%) but increased with RT-CGM use. In the adjusted analyses, HbA(1c) target attainment was associated with a lower risk of preterm birth, large-for-gestational age and neonatal hypoglycemia. We conclude that CONCEPTT trial participants had a low rate of CGM and of HbA(1c) target attainment. Attainment of CGM and NICE HbA(1c) targets increased throughout gestation and all targets (both NICE/ADA HbA(1c) and CGM) were more likely to be achieved by RT-CGM users, at 34 weeks' gestation. ADA HbA(1c) target achievement was independently associated with better perinatal outcomes, while the independent association of TBR target achievement with increased risk warrants further study. ClinicalTrials.gov Registration Identifier NCT01788527.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4672
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573793
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4672
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573793
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MARY ANN LIEBERT, INC
publisher.none.fl_str_mv MARY ANN LIEBERT, INC
dc.source.none.fl_str_mv Diabetes Technology & Therapeutics
ISSN: 15209156
ISSNe: 15578593
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425518902771712
score 15,198674

Registos relacionados